Literature DB >> 28273786

Influence of statin therapy at time of stroke onset on functional outcome among patients with atrial fibrillation.

Darae Ko1, Jonathan L Thigpen2, James A Otis3, Kristen Forster4, Lori Henault5, Emily Quinn6, Yorghos Tripodis6, Peter B Berger4, Nita Limdi7, Elaine M Hylek5.   

Abstract

BACKGROUND: Statin pretreatment has been associated with reduced infarct volume in nonlacunar strokes. The effect of statins on functional outcomes of strokes related to atrial fibrillation (AF) is unknown. We aimed to define the influence of prestroke statin use on functional outcome in AF.
METHODS: We assembled a cohort of consecutive ischemic stroke patients from 2006 to 2010. All patients underwent CT or MRI and were adjudicated by site investigators. AF was confirmed by electrocardiogram in 100% of patients. Site neurologists blinded to the study hypothesis affirmed the type of stroke and assessed the severity of disability at the time of hospital discharge. The frequency of death at 30-days was calculated.
RESULTS: Ischemic stroke (n=1030) resulted in a severe neurological deficit or death (modified Rankin scale ≥4) at 30days in 711 patients (69%). Using multivariable logistic regression models adjusting for factors associated with statin treatment and factors associated with functional outcome, prestroke statin use was associated with a 32% reduction in frequency of severe stroke (odds ratio [OR], 0.68; 95% confidence interval [CI], 0.50-0.92; P=0.011). Other independent factors associated with severe stroke included older age, female sex, non-White race, diabetes mellitus, prior ischemic stroke, prior venous thromboembolism, and dementia.
CONCLUSION: Ischemic strokes in AF are associated with high mortality and morbidity. Statin use at time of stroke onset among patients with AF was associated in this study with less severe stroke and warrant validation.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Atrial fibrillation; Hydroxymethylglutaryl-CoA reductase inhibitors; Risk factors; Stroke; Therapy

Mesh:

Substances:

Year:  2016        PMID: 28273786      PMCID: PMC5347145          DOI: 10.1016/j.ijcard.2016.10.055

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  36 in total

1.  Impact of lipid-lowering therapy on outcomes in atrial fibrillation.

Authors:  Apurva O Badheka; Ankit Rathod; Mohammad A Kizilbash; Neha Garg; Tamam Mohamad; Luis Afonso; Sony Jacob
Journal:  Am J Cardiol       Date:  2010-04-27       Impact factor: 2.778

2.  Cerebral vascular accidents in patients over the age of 60. II. Prognosis.

Authors:  J RANKIN
Journal:  Scott Med J       Date:  1957-05       Impact factor: 0.729

3.  Simvastatin given for 3 days can inhibit thrombin generation and activation of factor V and enhance factor Va inactivation in hypercholesterolemic patients.

Authors:  Anetta Undas; Magdalena Celinska-Löwenhoff; Kathleen E Brummel-Ziedins; Jan Brozek; Andrew Szczeklik; Kenneth G Mann
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-07       Impact factor: 8.311

4.  Interobserver agreement for the assessment of handicap in stroke patients.

Authors:  J C van Swieten; P J Koudstaal; M C Visser; H J Schouten; J van Gijn
Journal:  Stroke       Date:  1988-05       Impact factor: 7.914

Review 5.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.

Authors:  Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy
Journal:  J Am Coll Cardiol       Date:  2014-03-28       Impact factor: 24.094

6.  Effects of atorvastatin and rosuvastatin on thromboxane-dependent platelet activation and oxidative stress in hypercholesterolemia.

Authors:  Luca Puccetti; Francesca Santilli; Anna Laura Pasqui; Stefano Lattanzio; Rossella Liani; Federica Ciani; Elisabetta Ferrante; Giovanni Ciabattoni; Francesca Scarpini; Anna Ghezzi; Alberto Auteri; Giovanni Davì
Journal:  Atherosclerosis       Date:  2010-11-05       Impact factor: 5.162

7.  The risk of venous thromboembolism is markedly elevated in patients with diabetes.

Authors:  V Petrauskiene; M Falk; I Waernbaum; M Norberg; J W Eriksson
Journal:  Diabetologia       Date:  2005-03-19       Impact factor: 10.122

8.  Statin use is independently associated with smaller infarct volume in nonlacunar MCA territory stroke.

Authors:  Steven J Shook; Rishi Gupta; Nirav A Vora; Andrew L Tievsky; Irene Katzan; Derk W Krieger
Journal:  J Neuroimaging       Date:  2006-10       Impact factor: 2.486

9.  Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways.

Authors:  Masato Eto; Toshiyuki Kozai; Francesco Cosentino; Hana Joch; Thomas F Lüscher
Journal:  Circulation       Date:  2002-04-16       Impact factor: 29.690

10.  Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis.

Authors:  S Colli; S Eligini; M Lalli; M Camera; R Paoletti; E Tremoli
Journal:  Arterioscler Thromb Vasc Biol       Date:  1997-02       Impact factor: 8.311

View more
  9 in total

1.  Low-dose statin pretreatment reduces stroke severity and improves functional outcomes.

Authors:  Shuju Dong; Jian Guo; Jinghuan Fang; Ye Hong; Shuhui Cui; Li He
Journal:  J Neurol       Date:  2019-08-29       Impact factor: 4.849

2.  Overview the effect of statin therapy on dementia risk, cognitive changes and its pathologic change: a systematic review and meta-analysis.

Authors:  Xi-Chen Zhu; Wen-Zhuo Dai; Tao Ma
Journal:  Ann Transl Med       Date:  2018-11

3.  The Effect of Statin Treatment on Outcomes of Cardioembolic Stroke: A Systematic Review and Meta-Analysis of Real-World Studies.

Authors:  Tao Xu; You Wang; Jinxian Yuan; Yangmei Chen
Journal:  CNS Drugs       Date:  2021-05-21       Impact factor: 5.749

4.  Study Progress of the Influence of Atrial Fibrillation Treatment on Dementia.

Authors:  Xiao-Han Yan; Yong-Quan Wu
Journal:  Chin Med J (Engl)       Date:  2018-04-05       Impact factor: 2.628

5.  Beneficial effects of pre-stroke statins use in cardioembolic stroke patients with atrial fibrillation: a hospital-based retrospective analysis.

Authors:  Dariusz Kotlęga; Monika Gołąb-Janowska; Agnieszka Meller; Anna Bajer-Czajkowska; Agnieszka Zembroń-Łacny; Przemysław Nowacki; Maciej Banach
Journal:  Arch Med Sci       Date:  2019-03-04       Impact factor: 3.318

6.  Plasma D-dimer level is associated with clinical outcomes in patients with atrial fibrillation related acute ischemic stroke after pneumonia.

Authors:  Xu Yang; Taoli Lu; Zhanli Qu; Yi Zhang; Pingping Liu; Ying Ma
Journal:  BMC Neurol       Date:  2021-03-27       Impact factor: 2.474

7.  Effect of Statins on Survival Following Stroke in Patients With Cancer.

Authors:  Ye Sel Kim; Moo-Seok Park; Jun-Hwa Lee; Jong-Won Chung; Mi Ji Lee; Chi Kyung Kim; Jin-Man Jung; Kyungmi Oh; Oh Young Bang; Geong-Moon Kim; Ji-Mi Choi; Juneyoung Lee; Chin Sang Chung; Kwang Ho Lee; Woo-Keun Seo
Journal:  Front Neurol       Date:  2018-04-24       Impact factor: 4.003

8.  Prestroke statins use reduces oxidized low density lipoprotein levels and improves clinical outcomes in patients with atrial fibrillation related acute ischemic stroke.

Authors:  Lanying He; Ronghua Xu; Jian Wang; Lili Zhang; Lijuan Zhang; Wang Zhao; Weiwei Dong
Journal:  BMC Neurol       Date:  2019-10-18       Impact factor: 2.474

9.  Association of prestroke medicine use and health outcomes after ischaemic stroke in Sweden: a registry-based cohort study.

Authors:  Lekander Ingrid; Mia von Euler; Katharina S Sunnerhagen
Journal:  BMJ Open       Date:  2020-03-29       Impact factor: 2.692

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.